NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONJESTA is an oral extended-release tablet combining doxylamine succinate (a sedating antihistamine) and pyridoxine hydrochloride (vitamin B6) indicated for nausea and vomiting of pregnancy (NVP). The combination leverages doxylamine's antihistamine properties to reduce nausea while pyridoxine addresses pregnancy-related vitamin deficiency, offering a non-teratogenic alternative to manage morning sickness.
$0.039BPart D
Peak6.5 years to LOEProduct is at peak lifecycle stage with modest Part D uptake (61 claims in 2023), suggesting a niche, stable indication with limited commercial scaling opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Started May 2022
274 enrolled
Morning Sickness
Career Relevance
Working on BONJESTA offers stable, specialized OB/GYN expertise in a non-competitive, well-protected market, but limited upside growth or career expansion potential. This is a maintenance-mode product ideal for deep therapeutic area knowledge but not for building broad oncology, immunology, or high-growth portfolio experience.
Brand Manager
Worked on BONJESTA at Duchesnay? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.